山东亚华电子股份有限公司董事会 2025 年 4 月 19 日 山东亚华电子股份有限公司 董事会对独立董事独立性评估的专项意见 根据《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等 法律法规、规章、规范性文件及《公司章程》《独立董事工作制度》的相关要求， 山东亚华电子股份有限公司（以下简称"公司"）董事会，就公司在任独立董事吴 忠堂先生、罗治洪先生、赵毅新女士的独立性情况进行评估并出具如下专项意见： 经核查独立董事吴忠堂先生、罗治洪先生、赵毅新女士的任职经历以及签署的 相关自查文件，公司董事会认为上述人员未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系 或其他可能妨碍其进行独立客观判断的关系，不存在其他影响独立董事独立性的情 况，因此，公司独立董事符合《上市公司独立董事管理办法》《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》中对独立董事独立性的 相关要求。 ...

山东亚华电子股份有限公司 山东亚华电子股份有限公司 独立董事 2024 年度述职报告 （罗治洪） 各位股东及股东代表： 本人作为山东亚华电子股份有限公司（以下简称"公司"）的独立董事，在任 职期间严格按照《中华人民共和国公司法》（以下简称"《公司法》"）《中华人 民共和国证券法》（以下简称"《证券法》"）《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》《上市公司独立董事管理办法》《公 司章程》《独立董事工作制度》等法律法规、规章、规范性文件的相关规定和要求， 忠实勤勉履职，关心、关注公司经营发展，积极出席相关会议，认真审议各项议案， 充分发挥独立董事及各专门委员会委员的作用，维护公司整体利益和全体股东特别 是中小股东的合法权益。现就本人 2024 年度的履职情况汇报如下： 一、独立董事的基本情况 罗治洪，1976 年 10 月出生，中国国籍，无境外永久居留权，博士研究生学历。 2005 年 4 月至今，任昆明理工大学管理与经济学院副教授；2020 年 12 月至今，任 公司独立董事。 山东亚华电子股份有限公司 席，没有缺席或连续两次未亲自出席会议的情况。作为公司独立董事，本着勤勉、 ...

山东亚华电子股份有限公司 山东亚华电子股份有限公司 独立董事 2024 年度述职报告 （赵毅新） 各位股东及股东代表： 本人作为山东亚华电子股份有限公司（以下简称"公司"）的独立董事，在任 职期间严格按照《中华人民共和国公司法》（以下简称"《公司法》"）《中华人 民共和国证券法》（以下简称"《证券法》"）《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》《上市公司独立董事管理办法》《公 司章程》《独立董事工作制度》等法律法规、规章、规范性文件的相关规定和要求， 忠实勤勉履职，关心、关注公司经营发展，积极出席相关会议，认真审议各项议案， 充分发挥独立董事及各专门委员会委员的作用，维护公司整体利益和全体股东特别 是中小股东的合法权益。现就本人 2024 年度的履职情况汇报如下： 一、独立董事的基本情况 赵毅新，1956 年 4 月出生，中国国籍，无境外永久居留权，本科学历。历任 山东新华医疗器械厂分厂副厂长、党支书；山东新华医疗器械股份有限公司董事、 副总经理；山东新华医疗器械股份有限公司董事、总经理；山东新华医疗器械股份 有限公司董事长、党委书记，2017 年 8 月退休；2020 年 ...

山东亚华电子股份有限公司 山东亚华电子股份有限公司 独立董事 2024 年度述职报告 （吴忠堂） 一、独立董事的基本情况 各位股东及股东代表： 吴忠堂，1965 年 12 月出生，中国国籍，无境外永久居留权，博士研究生学历， 非执业注册会计师。历任解放军防化指挥工程学院讲师；和记奥普泰通信技术有限 公司质量测试经理；亿阳信通股份有限公司财务部副主任、运营办主任；北京紫光 展讯科技有限公司运营中心主任；2017 年 12 月至今，任新恒汇电子股份有限公司 董事、副总经理、财务负责人；2020 年 12 月至今，任公司独立董事。 本人作为山东亚华电子股份有限公司（以下简称"公司"）的独立董事，在任 职期间严格按照《中华人民共和国公司法》（以下简称"《公司法》"）《中华人 民共和国证券法》（以下简称"《证券法》"）《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》《上市公司独立董事管理办法》《公 司章程》《独立董事工作制度》等法律法规、规章、规范性文件的相关规定和要求， 忠实勤勉履职，关心、关注公司经营发展，积极出席相关会议，认真审议各项议案， 充分发挥独立董事及各专门委员会委员的作用，维 ...

Core Viewpoint - The company reported a significant decline in revenue and a net loss for the year 2024, indicating a challenging financial situation [1] Financial Performance - The company's operating revenue for 2024 is 218 million yuan, representing a year-on-year decrease of 37.97% [1] - The net loss attributable to shareholders is 26.4861 million yuan, a reversal from a net profit of 45.5168 million yuan in the same period last year [1] - Basic earnings per share are reported at -0.25 yuan per share [1] Dividend Policy - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves [1]

Financial Performance - The net profit attributable to shareholders for the reporting period was -26,486,052.99 RMB, a decrease of 158.19% compared to the same period last year[4]. - The company's operating revenue for 2024 was ¥217,910,015.34, a decrease of 37.97% compared to ¥351,310,084.13 in 2023[22]. - The net profit attributable to shareholders for 2024 was -¥26,486,052.99, representing a decline of 158.19% from ¥45,516,763.94 in 2023[22]. - The net cash flow from operating activities for 2024 was -¥50,334,778.04, a significant drop of 531.51% compared to -¥7,970,508.38 in 2023[22]. - The total assets at the end of 2024 were ¥1,223,315,775.74, down 5.37% from ¥1,292,728,742.95 at the end of 2023[22]. - The company's basic earnings per share for 2024 was -¥0.25, a decrease of 151.02% from ¥0.49 in 2023[22]. - The weighted average return on equity for 2024 was -2.34%, a decline of 7.91% compared to 5.57% in 2023[22]. - Total revenue for 2024 was ¥217,910,015.34, a decrease of 37.97% compared to ¥351,310,084.13 in 2023[85]. - Revenue from the hospital intelligent communication interaction system was ¥215,745,562.86, down 38.40% from ¥350,237,733.77 in the previous year[85]. - Domestic market revenue was ¥211,207,767.02, representing a 39.22% decline from ¥347,518,907.39 in 2023[85]. Investment and R&D - The company plans to continue investing in new technologies to enhance product competitiveness and seize opportunities in the medical field, particularly in the renovation of old hospital wards[4]. - The company aims to increase R&D investment to create integrated solutions that enhance clinical and management value in hospitals[72]. - The company is actively developing solutions based on OpenHarmony for the medical sector, contributing to the sustainable development of the OpenHarmony ecosystem[71]. - The company has established R&D centers in multiple cities, focusing on a comprehensive R&D system that aligns closely with market needs[74]. - The company has a strong emphasis on R&D, with a total of 153 authorized patents and 242 software copyrights as of December 31, 2024, indicating a commitment to innovation[69]. - The company plans to invest 50 million yuan in R&D for new technologies aimed at enhancing product efficiency[169]. - Research and development expenses increased by 30% to 150 million, focusing on innovative technologies[178]. Market Strategy and Expansion - The company aims to improve internal management and budget management to reduce costs and increase efficiency while consolidating the domestic market and expanding into overseas markets[4]. - The company is actively increasing investment in market expansion efforts[4]. - The company anticipates increased demand for smart hospital solutions due to government policies promoting equipment upgrades and new hospital constructions[131]. - The company plans to enhance its overseas market presence by targeting hospital clients and leveraging B2B online platforms[131]. - The company is exploring potential mergers and acquisitions to strengthen its market position[1]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by 2025[178]. Challenges and Risks - The company faces challenges due to intensified industry competition and delayed market demand release, impacting revenue expectations[4]. - The company acknowledges the risks associated with future plans and encourages investors to be aware of these risks[5]. - The company is exposed to risks related to core technology leakage and talent loss, which could negatively impact product competitiveness and R&D progress[133]. - The company recognizes the risk of new product development delays and is committed to continuous R&D investment to meet evolving customer needs[132]. - The company faces seasonal risks as sales and cash collections are concentrated in the second half of the year, affecting revenue and profit distribution[136]. Corporate Governance and Management - The company has conducted three shareholder meetings during the reporting period, ensuring compliance with governance regulations[145]. - The company held 6 supervisory board meetings during the reporting period, ensuring effective oversight of the board's decision-making processes and compliance with legal operations[148]. - The company maintains complete independence from its controlling shareholders in terms of business, personnel, assets, and finance, ensuring autonomous operational capabilities[152]. - The performance evaluation of senior management combines quantitative and qualitative methods, linking compensation to responsibilities and contributions[149]. - The company has designated multiple channels for investor communication, including its website and dedicated phone lines, to ensure transparency and timely responses[148]. Employee and Training Initiatives - The total number of employees at the end of the reporting period is 604, with 509 from the parent company and 95 from major subsidiaries[181]. - The company has 163 core technical personnel, accounting for 26.99% of total employees, with their salaries representing 35.05% of the total salary expenses[183]. - The company successfully organized over 10 large training events in 2024, with more than 300 employees participating, significantly enhancing team skills and corporate culture awareness[184]. - The company recognizes the need to continuously improve training content and effectiveness, committing to enhance the training system for better employee development[185]. Financial Management and Dividend Policy - The company will not distribute cash dividends, issue bonus shares, or increase share capital from reserves[6]. - The company has a clear strategy for maintaining independence from its controlling shareholders, with no circumstances that could compromise its operational autonomy[152]. - The company has established a transparent profit distribution policy to protect the rights of minority shareholders and encourage long-term investment[187]. - The company plans to maintain a cash dividend policy, ensuring that cash distributions will not be less than 10% of the distributable profits for the year[190]. - The total distributable profit for the company is approximately ¥153.5 million, with no cash dividends distributed this period[195].

证券代码：301337 证券简称：亚华电子 公告编号：2025-008 1、持有山东亚华电子股份有限公司（以下简称"本公司"、"公司"）股 份 372,600 股（占公司总股本比例 0.36%）的董事、副总经理宋庆计划在本减持 计划公告之日起十五个交易日后的三个月内（即 2025 年 4 月 3 日至 2025 年 7 月 2 日期间，在此期间如遇法律法规规定的窗口期则不减持）以集中竞价或大宗交 易方式减持公司股份不超过 90,000 股（占本公司总股本比例 0.09%）。 2、持有本公司股份 190,000 股（占公司总股本比例 0.18%）的董事唐泽远计 划在本减持计划公告之日起十五个交易日后的三个月内（即 2025 年 4 月 3 日至 2025 年 7 月 2 日期间，在此期间如遇法律法规规定的窗口期则不减持）以集中 竞价或大宗交易方式减持公司股份不超过 40,000 股（占本公司总股本比例 0.04%）。 山东亚华电子股份有限公司 关于部分董事、高级管理人员减持股份的预披露公告 公司董事、副总经理宋庆，董事唐泽远，董事会秘书、财务总监于雷保证向 本公司提供的信息内容真实、准确、完整，没有虚假记载、误 ...

证券代码：301337 证券简称：亚华电子 公告编号：2025-007 公司前期在中信证券（山东）淄博分公司开立了募集资金现金管理专用结算 账户，用于对部分闲置募集资金进行现金管理，具体内容详见公司于2023年10月 31日在巨潮资讯网（www.cninfo.com.cn）上披露的相关公告。鉴于上述现金管 理专用结算账户已不再使用且无后续使用计划，公司已于近期将相关账户注销， 具体注销的账户信息如下： | 序号 | 开户名称 | 开户机构 | 资金账号 | | --- | --- | --- | --- | | 1 | 山东亚华电子股份有限公司 | 中信证券（山东）淄博分公司 | 9915590070 | 二、开立募集资金现金管理专用结算账户情况 近日，公司开立了募集资金现金管理专用结算账户，现将相关情况公告如下： 山东亚华电子股份有限公司 关于注销及开立募集资金现金管理专用结算账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东亚华电子股份有限公司（以下简称"公司"）于2024年12月6日召开的 第三届董事会第十六次会议、第三届监事会第十三次会议 ...

Financial Performance Expectations - The company expects a net loss of between 21 million and 29 million RMB for 2024, compared to a profit of 45.52 million RMB in the same period last year[4]. - The expected net profit after deducting non-recurring gains and losses is projected to be a loss of 26 million to 37 million RMB, down from a profit of 44.35 million RMB in the previous year[4]. - The overall gross profit margin is expected to decline due to falling market prices for main products amid increasing competition[6]. - The financial forecast is based on preliminary calculations by the finance department and has not been audited by the accounting firm[8]. - Detailed financial data for 2024 will be disclosed in the annual report, urging investors to make cautious decisions and be aware of investment risks[8]. Market and Competition - The decline in revenue is attributed to intensified competition in domestic hospital construction projects, leading to lower-than-expected market expansion and a decrease in main business income[6]. - The company is committed to seizing opportunities in the medical field, particularly in the renovation of old hospital wards[7]. Strategic Initiatives - The company will continue to invest in new technologies to enhance product competitiveness and focus on providing integrated software and hardware solutions for users[6]. - The company aims to improve internal management and strengthen budget management to reduce costs and increase efficiency[7]. Non-Recurring Gains - The company anticipates a non-recurring gain of 6 million to 8 million RMB, primarily from financial investment income[7].

证券代码：301337 证券简称：亚华电子 公告编号：2025-003 山东亚华电子股份有限公司 第四届监事会第一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 山东亚华电子股份有限公司（以下简称"公司"）第四届监事会第一次会 议于 2025 年 1 月 3 日（星期五）在公司会议室以现场结合通讯的方式召开。为 保证监事会工作的连续性，会议于 2025 年 1 月 3 日在公司 2025 年第一次临时股 东大会选举产生第四届监事会成员后，经全体监事同意豁免会议通知时间要求， 以电话、口头通知等方式送达全体监事。本次会议应出席监事 3 人，实际出席监 事 3 人（其中荆凯监事以通讯方式出席）。 出席会议的监事对各项议案进行了认真审议并做出了如下决议： （一）审议通过《关于选举公司第四届监事会主席的议案》 根据《公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》及《公司章程》等有关规定，第四届监事会同意选举荆凯先 生为公司第四届监事会主席，任期自本次监事会审议通过之日起至公司第四届监 事会届 ...